grade
pharmaceutical primary standard
API family
chlorthalidone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23
InChI
1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
InChI key
JIVPVXMEBJLZRO-UHFFFAOYSA-N
Gene Information
human ... SLC12A3(6559)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Chlorthalidone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Chlorthalidone Tablets
- Atenolol and Chlorthalidone Tablets
- Clonidine Hydrochloride and Chlorthalidone Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Disclaimer
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 氯噻酮
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
Edarbyclor: an ARB/chlorthalidone combination for hypertension.
The Medical letter on drugs and therapeutics, 54(1385), 17-18 (2012-03-03)
Massimo Cirillo et al.
Hypertension (Dallas, Tex. : 1979), 63(4), 692-697 (2014-01-08)
Short-term effects of chlorthalidone are unknown in low kidney function. The effects of 8-week treatment with 25-mg chlorthalidone on the top of ongoing treatment were compared between control hypertensives and low kidney function hypertensives as assessed by estimated glomerular filtration
Jerrica E Shuster et al.
Vascular health and risk management, 8, 381-387 (2012-06-30)
Azilsartan-chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1130006-200MG | 04061838700742 |